Victoria A Brentville, Suha Atabani, Katherine Cook, Lindy G Durrant
{"title":"Novel tumour antigens and the development of optimal vaccine design.","authors":"Victoria A Brentville, Suha Atabani, Katherine Cook, Lindy G Durrant","doi":"10.1177/2515135518768769","DOIUrl":null,"url":null,"abstract":"<p><p>The interplay between tumours and the immune system has long been known to involve complex interactions between tumour cells, immune cells and the tumour microenvironment. The progress of checkpoint inhibitors in the clinic in the last decade has highlighted again the role of the immune system in the fight against cancer. Numerous efforts have been undertaken to develop ways of stimulating the cellular immune response to eradicate tumours. These interventions include the identification of appropriate tumour antigens as targets for therapy. In this review, we summarize progress in selection of target tumour antigen. Targeting self antigens has the problem of thymic deletion of high-affinity T-cell responses leaving a diminished repertoire of low-affinity T cells that fail to kill tumour cells. Thymic regulation appears to be less stringent for differentiation of cancer-testis antigens, as many tumour rejection antigens fall into this category. More recently, targeting neo-epitopes or post-translational modifications such as a phosphorylation or stress-induced citrullination has shown great promise in preclinical studies. Of particular interest is that the responses can be mediated by both CD4 and CD8 T cells. Previous vaccines have targeted CD8 T-cell responses but more recently, the central role of CD4 T cells in orchestrating inflammation within tumours and also differentiating into potent killer cells has been recognized. The design of vaccines to induce such immune responses is discussed herein. Liposomally encoded ribonucleic acid (RNA), targeted deoxyribonucleic acid (DNA) or long peptides linked to toll-like receptor (TLR) adjuvants are the most promising new vaccine approaches. These exciting new approaches suggest that the 'Holy Grail' of a simple nontoxic cancer vaccine may be on the horizon. A major hurdle in tumour therapy is also to overcome the suppressive tumour environment. We address current progress in combination therapies and suggest that these are likely to show the most promise for the future.</p>","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"6 2","pages":"31-47"},"PeriodicalIF":0.0000,"publicationDate":"2018-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5933538/pdf/10.1177_2515135518768769.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Vaccines and Immunotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/2515135518768769","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2018/4/10 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
The interplay between tumours and the immune system has long been known to involve complex interactions between tumour cells, immune cells and the tumour microenvironment. The progress of checkpoint inhibitors in the clinic in the last decade has highlighted again the role of the immune system in the fight against cancer. Numerous efforts have been undertaken to develop ways of stimulating the cellular immune response to eradicate tumours. These interventions include the identification of appropriate tumour antigens as targets for therapy. In this review, we summarize progress in selection of target tumour antigen. Targeting self antigens has the problem of thymic deletion of high-affinity T-cell responses leaving a diminished repertoire of low-affinity T cells that fail to kill tumour cells. Thymic regulation appears to be less stringent for differentiation of cancer-testis antigens, as many tumour rejection antigens fall into this category. More recently, targeting neo-epitopes or post-translational modifications such as a phosphorylation or stress-induced citrullination has shown great promise in preclinical studies. Of particular interest is that the responses can be mediated by both CD4 and CD8 T cells. Previous vaccines have targeted CD8 T-cell responses but more recently, the central role of CD4 T cells in orchestrating inflammation within tumours and also differentiating into potent killer cells has been recognized. The design of vaccines to induce such immune responses is discussed herein. Liposomally encoded ribonucleic acid (RNA), targeted deoxyribonucleic acid (DNA) or long peptides linked to toll-like receptor (TLR) adjuvants are the most promising new vaccine approaches. These exciting new approaches suggest that the 'Holy Grail' of a simple nontoxic cancer vaccine may be on the horizon. A major hurdle in tumour therapy is also to overcome the suppressive tumour environment. We address current progress in combination therapies and suggest that these are likely to show the most promise for the future.
众所周知,肿瘤与免疫系统之间的相互作用涉及肿瘤细胞、免疫细胞和肿瘤微环境之间复杂的相互作用。近十年来,检查点抑制剂在临床上取得的进展再次凸显了免疫系统在抗癌中的作用。为开发刺激细胞免疫反应以根除肿瘤的方法,人们做出了大量努力。这些干预措施包括确定适当的肿瘤抗原作为治疗目标。在这篇综述中,我们总结了在选择目标肿瘤抗原方面取得的进展。靶向自身抗原存在胸腺删除高亲和力T细胞反应的问题,导致低亲和力T细胞库减少,无法杀死肿瘤细胞。胸腺调节对癌症-睾丸抗原的分化似乎不那么严格,因为许多肿瘤排斥抗原都属于这一类。最近,针对新表位或翻译后修饰(如磷酸化或应激诱导的瓜氨酸化)的临床前研究已显示出巨大的前景。尤其令人感兴趣的是,CD4 和 CD8 T 细胞都能介导这种反应。以前的疫苗以 CD8 T 细胞反应为目标,但最近人们认识到 CD4 T 细胞在协调肿瘤内炎症反应和分化为强效杀伤细胞方面的核心作用。本文将讨论如何设计疫苗来诱导这种免疫反应。脂质体编码核糖核酸(RNA)、靶向脱氧核糖核酸(DNA)或与收费样受体(TLR)佐剂相连的长肽是最有前途的新疫苗方法。这些令人振奋的新方法表明,简单无毒的癌症疫苗 "圣杯 "可能即将问世。肿瘤治疗的一大障碍也是克服抑制性肿瘤环境。我们讨论了目前在联合疗法方面取得的进展,并认为这些疗法很可能在未来大有可为。